ODI Pharma AB (“ODI” or the “Company”) today announces a reverse profit warning following a significantly strong revenue development for the period October–December 2025 (Q2).   Preliminary and unaudited figures indicate that ODI achieved revenues of approximately SEK 11 million during the second quarter 2025/2026. This corresponds to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial increase compared to the corresponding quarter of the prev

The Board of Directors of ODI Pharma AB (publ) (“ODI Pharma” or the “Company”) has resolved to propose a directed share issue of...

The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025....

Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting...